• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

    17.78 -0.36 (-1.98%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 29, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,880,741
    Open 17.91
    Bid (Size) 17.77 (100)
    Ask (Size) 17.88 (500)
    Prev. Close 18.14
    Today's Range 17.75 - 18.15
    52wk Range 15.55 - 36.91
    Shares Outstanding 97,381,774
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
    As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Emissions
    News headline image
    Up Nearly 400% This Year, Can Oklo Stock Still Rise Higher? ↗
    Many investors see this nuclear power company as a possible answer to the growing energy needs from artificial intelligence, and it has benefited from that. 
    Via The Motley Fool
    Topics Artificial Intelligence

    Performance

    YTD
    -3.1%
    -3.1%
    1 Month
    +3.0%
    +3.0%
    3 Month
    -16.0%
    -16.0%
    6 Month
    -16.4%
    -16.4%
    1 Year
    -0.6%
    -0.6%

    More News

    Read More
    Summit Therapeutics Stock Sparks Retail Buzz After Ivonescimab Combo Cuts Cancer Progression Risk By 40% ↗
    Via Stocktwits
    News headline image
    An Overview of Summit Therapeutics's Earnings ↗
    Via Benzinga
    News headline image
    2 Stocks Up Over 600% in the Past 3 Years With More Room to Run ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? ↗
    Via The Motley Fool
    News headline image
    Don't Buy Summit Therapeutics Until This Big Thing Happen ↗
    Via The Motley Fool
    News headline image
    2 Monster Stocks in the Making to Buy and Hold ↗
    Via The Motley Fool
    News headline image
    Summit SMMT Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics to Present at Upcoming Investor Conferences
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Alpha Buying: When Insiders Buy Big & Why It Works in Every Market ↗
    Via Benzinga
    News headline image
    Why Wall Street Is Backing These 3 Comeback Stocks ↗
    Via MarketBeat
    News headline image
    1 Monster Stock in the Making to Buy and Hold ↗
    Via The Motley Fool
    News headline image
    Summit Therapeutics: A Risky Bet in the Biotech Arena? ↗
    Via The Motley Fool
    News headline image
    Summit Therapeutics Raises $500 Million in Private Placement
    From Summit Therapeutics
    Via Business Wire
    News headline image
    What's Going On With Summit Therapeutics Stock On Monday? ↗
    Via Benzinga
    News headline image
    Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More ↗
    Via Benzinga
    News headline image
    Summit Therapeutics Inc (NASDAQ:SMMT) Reports Wider-Than-Expected Q3 2025 Loss ↗
    Via Chartmill
    News headline image
    Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Earnings Scheduled For October 20, 2025 ↗
    Via Benzinga
    News headline image
    Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
    From Summit Therapeutics
    Via Business Wire

    Frequently Asked Questions

    Is Summit Therapeutics Inc. - Common Stock publicly traded?
    Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Summit Therapeutics Inc. - Common Stock trade on?
    Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
    The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
    What is the current price of Summit Therapeutics Inc. - Common Stock?
    The current price of Summit Therapeutics Inc. - Common Stock is 17.78
    When was Summit Therapeutics Inc. - Common Stock last traded?
    The last trade of Summit Therapeutics Inc. - Common Stock was at 12/29/25 04:00 PM ET
    What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
    The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.73B
    How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
    Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.